Orphenadrine is a muscarinic antagonist used as an adjunct for the symptomatic relief of musculoskeletal pain and discomfort. A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.
- Mechanism
- Curator reviewed
Orphenadrine binds and inhibits both histamine H1 receptors and NMDA receptors. It restores the motor disturbances induced by neuroleptics, in particular the hyperkinesia. The dopamine deficiency in the striatum increases the stimulating effects of the cholinergic system. This stimulation is counteracted by the anticholinergic effect of orphenadrine. It may have a relaxing effect on skeletal muscle spasms and it has a mood elevating effect.
- Primary indication
- Indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculo skeletal conditions.Curator reviewed · 17 structured indications
- Formula / weight
- C18H23NO · 269.3813 g/mol (avg)
- First approval
- Canada, 2005 · United States, 1959
- Brand names
Resolves to
QVYRGXJJSLMXQH-UHFFFAOYSA-NSMILESCN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1CWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Orphenadrine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account